睿知中国医院研究地图
候选清单

即将招募胰腺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

ClinicalTrials.gov 上登记的一项胰腺癌开放试验,由浙江大学医学院附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06888674,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed pancreatic ductal adenocarcinoma (PDAC) post-surgery;

    入选标准第 18 条

  3. Contraception agreement: Fertile males and females of childbearing potential must agree to use effective contraception from signing the ICF until 6 months after the last dose of study treatment. Females of childbearing potential include premenopausal women and women ≤2 years postmenopausal;

    入选标准第 12 条

    Serum CA 19-9 level >180 U/mL within 21 days prior to initiating standard postoperative adjuvant therapy;

    排除标准第 1 条

  4. ECOG Performance Status score of 0 or 1;

    入选标准第 6 条

    ECOG Performance Status score:Cohort A: 0 or 1;Cohort B: 0-2;

    入选标准第 20 条

  5. Liver function: Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN;

    入选标准第 9 条

    Renal function: Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min (Cockcroft-Gault formula);

    入选标准第 10 条

  6. HIV antibody-positive;

    排除标准第 10 条

    Active hepatitis C (HCV RNA-positive);

    排除标准第 12 条

    Active hepatitis B (HBsAg-positive and HBV DNA ≥2000 IU/mL);

    排除标准第 13 条

  7. Pregnancy or lactation;

    排除标准第 24 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06888674,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Pre-Screening Phase Inclusion Criteria (for Radical Surgery and Vaccine Preparation):
  2. Subjects meeting all of the following criteria will enter the pre-screening phase for radical surgery and vaccine preparation:
  3. Voluntarily sign the informed consent form (ICF);
  4. Age ≥18 years, regardless of gender;
  5. Diagnosed with resectable pancreatic cancer as assessed per the 2024 NCCN Clinical Practice Guidelines and willing to undergo radical surgery;
  6. ECOG Performance Status score of 0 or 1;
  7. Ability to obtain sufficient fresh tumor tissue samples for whole-exome sequencing (WES) and transcriptome sequencing analysis;
  8. Normal function of major organs (heart, liver, kidneys):
  9. Liver function: Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN;
  10. Renal function: Serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min (Cockcroft-Gault formula);
  11. Cardiac function: LVEF ≥50% by echocardiography;
  12. Contraception agreement: Fertile males and females of childbearing potential must agree to use effective contraception from signing the ICF until 6 months after the last dose of study treatment. Females of childbearing potential include premenopausal women and women ≤2 years postmenopausal;
  13. Ability to comply with the study protocol and follow-up procedures.
  14. Formal Screening Phase Inclusion Criteria (for Study Treatment Initiation):
  15. Subjects meeting all of the following criteria will enter the formal screening phase for study treatment:
  16. Voluntarily sign the informed consent form (ICF);
  17. Age ≥18 years, regardless of gender;
  18. Histologically confirmed pancreatic ductal adenocarcinoma (PDAC) post-surgery;
  19. Completion of radical resection (R0 or R1) with no evidence of metastatic disease, malignant ascites, or pleural effusion on imaging 4-12 weeks postoperatively;
  20. ECOG Performance Status score:Cohort A: 0 or 1;Cohort B: 0-2;
  21. Normal function of major organs (heart, liver, kidneys):
  22. Contraception agreement: Same as pre-screening criteria;
  23. Ability to comply with the study protocol and follow-up procedures.

排除标准:Exclusion Criteria:

  1. Serum CA 19-9 level >180 U/mL within 21 days prior to initiating standard postoperative adjuvant therapy;
  2. History of bone marrow transplantation, allogeneic organ transplantation, or allogeneic hematopoietic stem cell transplantation;
  3. Concurrent immunosuppressive therapy, defined as regular use of immunosuppressive agents within 4 weeks prior to screening or during the study, including but not limited to:
  4. Severe asthma requiring systemic corticosteroids (≥10 mg/day prednisone equivalent);
  5. Active autoimmune disease or immunodeficiency (e.g., rheumatoid arthritis, systemic lupus erythematosus);
  6. History of primary immunodeficiency;
  7. Exceptions: Type 1 diabetes, autoimmune hypothyroidism managed with hormone replacement, vitiligo, or psoriasis not requiring systemic therapy;
  8. Active bacterial/fungal infections requiring systemic treatment, or active/latent tuberculosis (confirmed by interferon-gamma release assay or tuberculin skin test);
  9. Active viral infections:
  10. HIV antibody-positive;
  11. Syphilis (TP antibody-positive with RPR/TRUST confirmation);
  12. Active hepatitis C (HCV RNA-positive);
  13. Active hepatitis B (HBsAg-positive and HBV DNA ≥2000 IU/mL);
  14. Acute viral infections:
  15. Herpesvirus infection (unless resolved with crusting >4 weeks prior);
  16. Respiratory viral infection (unless resolved >4 weeks prior);
  17. Uncontrolled comorbidities:
  18. Symptomatic congestive heart failure (NYHA Class III/IV);
  19. Unstable angina or arrhythmia requiring treatment;
  20. Severe coronary/cerebrovascular disease (e.g., myocardial infarction within 6 months);
  21. Other conditions deemed exclusionary by the investigator;
  22. History of drug abuse, psychiatric disorders, or psychosocial factors impairing informed consent or protocol compliance;
  23. History of severe hypersensitivity to vaccines, biologics, or any component of the study drug;
  24. Pregnancy or lactation;
  25. Other conditions judged by the investigator to preclude safe participation.

引自 ClinicalTrials.gov, NCT06888674, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06888674,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06888674